A
Abiochem Biotechnology
Developing new biocatalysis and synthetic biology processes
About Abiochem Biotechnology
A bio-intelligent manufacturing company with advanced synthetic biology technology, dedicated to the research and development of biocatalysts and biocatalytic processes for producing chiral chemicals.
The company operates as a biocatalysis solution provider, developing and manufacturing pharmaceutical intermediates, nutritional supplements, and other fine chemicals. It has established a strong foundation in the design and remake of enzymes, metabolic pathways, and chassis cells. The business model appears to be centered on leveraging its proprietary enzyme engineering and genetic engineering technologies to supply high-quality chiral chemicals and biocatalysis solutions to other businesses, likely in the pharmaceutical and chemical industries.
Established in 2015, the company has invested in R&D and has a high-quality, high-standard industrialization platform to support the development of the synthetic biology industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Minhang District, China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 76.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2021 | $46M | $184M | CMB International · Temasek · CMB International Capital | — |
| SERIES A✓Equity / VC | Nov 2020 | $0 | — | Huatai Zijin Investment · Binghong Capital · Haitong-Fortis Private Equity Fund Management · Zizhu Xiaomiao PE | — |
Growth signals
Latest recorded traffic for Abiochem Biotechnology is 300 monthly website visits, down 9.1% over the last three months. Abiochem Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Highlight Capital
Huatai Zijin Investment- BCBinghong Capital
- HMHaitong-Fortis Private Equity Fund Management
Zizhu Xiaomiao PE
Series B and later3 investors entered at this stage
Temasek
CMB International Capital- CICMB International
Other known investors2 additional known investors
Shanghai Jiao Tong University
Wuhan University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Abiochem Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Abiochem Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.